A post hoc analysis of RATIFY confirmed that midostaurin conferred survival benefits in FLT3-ITD AML across all three ELN risk groups, irrespective of the FLT3-ITD allelic burden or co-mutation profile (e.g., with or without NPM1 mutation) [11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.